Astera Labs CEO Mohan Jitendra sells $18.5m in stock

Astera Labs CEO Jitendra Mohan sold 123,750 shares for $18.52 million in two Form 4 transactions on April 10, 2026, with shares held indirectly through a Living Trust and remaining beneficial ownership of 4,407,982 shares. The sales were executed under a prearranged Rule 10b5-1 plan, which reduces the signaling impact, but they still represent notable insider selling. Separately, the company reported Q4 2025 EPS of $0.58 versus $0.51 expected and revenue of $270.6 million, up 92% year over year.

Analysis

The insider sale is not a bearish signal by itself, but it is a useful tell that management views the current setup as “good enough” to monetize after a very large rerating. With the stock already pricing in exceptional growth, the market is effectively paying for near-flawless execution; that creates asymmetry if growth merely normalizes from triple-digit to high-double-digit rates. The key second-order effect is that any deceleration in data-center capex or a wobble in AI networking demand will hit ALAB harder than the headline earnings beat suggests because multiple expansion has done most of the work.

More important than the sale is the balance between fundamental quality and valuation fragility. A company can post 90%+ revenue growth and still be a poor incremental buy if the next 12 months require sustained beats, margin stability, and no product-cycle hiccups to justify the current price. In that regime, insider monetization often marks the point where long-only ownership becomes crowded and upside depends on fresh flows rather than revised estimates.

The contrarian takeaway is that this is less a “sell the stock” setup than a “buy protection” setup. If the AI infrastructure trade stays intact, ALAB can remain expensive for longer than skeptics expect; but if the market rotates away from high-multiple semis or hyperscaler spend pauses, the drawdown can be fast because there is little valuation cushion. The catalyst window is short: one or two quarters of management guidance will determine whether the stock is still in a momentum phase or becomes a multiple-compression candidate.

Key Decisions for Investors

• Trim or hedge long ALAB exposure into strength; use a 1-3 month horizon because the setup is vulnerable to any guidance normalization, with downside risk disproportionately larger than upside from here.
• If holding ALAB, buy put spreads 5-10% below spot out 1-2 quarters to protect against a post-earnings de-rating; risk/reward favors defined-cost downside insurance over outright shorting.
• For relative value, pair long a lower-multiple AI infrastructure beneficiary versus short ALAB over the next 2 quarters; the idea is to capture continued AI spend while reducing valuation beta.
• Avoid adding fresh capital to ALAB until the next print confirms that growth and margins remain above consensus; a single miss could compress the multiple sharply given crowded ownership.